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a  1. Introduction 
Organizers of this 239th ENMC workshop welcomed 22
participants from 12 countries worldwide (Belgium, Canada,
China, the Czech Republic, France, Germany, Japan, The
Netherlands, Spain, Sweden, the United Kingdom, and
the United States of America) to Amsterdam on 14–16
December 2018 for this workshop on the clinicopathological
classification of dermatomyositis (DM). 
Idiopathic inflammatory myopathies (IIM) are a
heterogenous family of diseases that can affect the muscles,
skin, lungs, and joints. There have been prior attempts to
classify IIMs, including the highly influential classification
criteria for DM, polymyositis (PM), and immune-mediated
necrotizing myopathy (IMNM) resulting from the 119th
ENMC workshop in 2003 [1] . However, over the last 15 years,
considerable progress has been made in our understanding
of the IIMs that requires re-evaluation and re-formulation
of the earlier ENMC criteria. In particular, myositis-specific
autoantibodies are now recognized to define unique subgroups
of IIM. Although a data-driven classification system for
IIM was recently endorsed by the American College of
Rheumatology and the European League Against Rheumatism
[2 , 3] , that system does not include autoantibody-defined
subgroups. We recently proposed a classification system for
IMNM that includes autoantibody-defined subgroups at the∗ Corresponding author. 
E-mail address: andrew.mammen@nih.gov (A.L. Mammen). 
1 These authors contributed equally. 







0960-8966 24th ENMC workshop [4] . Here we propose to extend these
fforts by arriving at modernized classification criteria for DM
nd its subsets based on international consensus. To this end,
 team of 22 experts assembled to address the following goals:
– Consensus regarding a valid definition of DM 
– Consensus regarding a definition of DM diagnostic criteria
(clinical and pathological) 
– Presentation and discussion about animal-models suitable
for future research on DM 
– Consensus on the role of serology in DM 
– Proposition and discussion of treatment schemes for DM
(given the absence of clinical trials). 
. DM subtypes 
Over the last few decades, several DM-specific
utoantibodies have been discovered and each of these
as been associated with a unique clinical phenotype.
r. Andrew Mammen opened the workshop with a session
escribing the clinical features of patients with autoantibodies
ecognizing nuclear matrix protein (NXP) 2. Initially named
anti-MJ”, these autoantibodies were first recognized to exist
n ∼18% of juvenile DM patients [5] . After the protein
arget was identified as NXP2 [6] , it was shown that these
utoantibodies are associated with calcinosis in children with
M [7] . Approximately 17% of adult DM patients have
nti-NXP2 autoantibodies and initial reports suggested a
ossible association with cancer [8] . The association between
ancer and anti-NXP2 autoantibodies was confirmed in
ubsequent studies that also demonstrated an increased
















































































































f  revalence of subcutaneous edema, calcinosis, distal
eakness, dysphagia, and myalgia compared to adult DM
atients without these autoantibodies [9 , 10] . Another study
howed that anti-NXP2-positive juvenile DM patients are
eaker and less likely to enter remission than other children
ith DM [11] . 
An analysis of muscle biopsies from patients with different
M-specific autoantibodies revealed that lymphocytes 
urround and invade myofibers in 28% of muscle biopsies
rom DM patients with other autoantibodies [12] . However,
his pathologic finding was never observed in DM patients
ith anti-NXP2 autoantibodies. Despite these histological 
ifferences in muscle biopsy features, Dr. Mammen
resented preliminary data from gene expression profiling
tudies demonstrating that anti-NXP2 muscle tissue has a
rominent type I interferon signature that is indistinguishable
rom patients with other DM-specific autoantibodies 
13] . 
Next, Dr. Guochun Wang described the clinical features
f DM patients with autoantibodies recognizing transcription
ntermediary factor (TIF)1- γ . Also called TRIM33, TIF1- γ
s a multifunctional protein with complex effects on
everal cellular pathways, including immunoregulation and 
arcinogenesis [14] . In his Chinese cohort of DM patients,
he prevalence of anti-TIF1- γ autoantibodies was 19.2%;
o anti-TIF1- γ autoantibodies were found in other types
f IIM. Two types of skin rash were observed in patients
ith anti-TIF1- γ : one is a facial dermatosis which usually
omes with long-time disease course; the second type is
haracterized by a skin rash around the hairline. 
Muscle weakness is common in anti-TIF1- γ positive DM.
r. Wang presented data showing that 77.8% of Chinese
atients with anti-TIF1- γ had muscle involvement. Muscle
iopsy showed that approximately half of these presented
ith typical perifascicular atrophy and other DM-associated
athological features, 31% had nonspecific changes, and
 small portion ( ∼12%) had normal muscle pathology.
atients with anti-TIF1- γ autoantibodies less infrequently 
eveloped interstitial lung disease (ILD) compared with
nti-TIF1- γ negative DM patients; of note, the latter group
ncluded antisynthetase patients with DM-like rashes. He
lso noted that ILD in anti-TIF1- γ positive DM was usually
elatively mild and that rapidly progressive (RP)-ILD was
are. Dysphagia occurred in 43% of Chinese patients with
nti-TIF1- γ autoantibodies. 
A striking clinical feature of patients with anti-TIF1- γ
s an association with cancer. In the Chinese cohort studied
y Dr. Wang, 55% had malignancy. Moreover, among those
ith cancer-associated-myositis, 64% were positive for
nti-TIF1- γ autoantibodies. Compared with the age- and
ex-matched Chinese population, the incidence of cancer in
nti-TIF1- γ positive patients was markedly increased (SIR
alue = 17.82) [15] . These results are consistent with a
eta-analysis conducted by Prof. Albert Selva-O’Callaghan 
rom Spain, which showed that sensitivity and specificity of
nti-TIF1- γ autoantibodies for diagnosing cancer in myositis
as 78% and 89%, respectively [16] . In a further comparison of the clinical features between
nti-TIF1- γ positive patients with and without cancer, the age
f the disease onset in the group with cancer was significantly
lder than that of patients without cancer. Although there was
 trend for increased prevalence of dysphagia in patients with
ancer, this was not statistically significant. Moreover, other
ymptoms, including muscle weakness, arthritis, and ILD,
ere not significantly different between these two groups. Of
mportance, the survival rate was much lower in patients with
ancer than in patients without cancer. Dr. Wang presented
npublished data showing that the 5 years and 10 years
urvival rates in the Chinese anti-TIF1- γ DM patients with
ancer were only around 60% and 40%, respectively. In
ontrast, the 5 years and 10 years survival rates were higher
n the patients without cancer (both > 90%). 
Dr. Océane Landon-Cardinal presented next, explaining 
hat autoantibodies recognizing Mi2 were the first DM-
pecific serologic marker [17 , 18] . The prevalence of anti-Mi2
utoantibodies ranges from 2 to 45% in adult DM patients
nd from 4 to 10% in juvenile DM patients [19] . These
utoantibodies have been associated with the “classic” form
f DM, with hallmark cutaneous lesions as well as cuticular
vergrowth and periungueal hemorrhage [20] , mild muscle
isease, a low risk of ILD, and a good prognosis with a low
isk of cancer [21] . 
Dr. Landon-Cardinal shared unpublished data from a
rench cohort of 64 anti-Mi2-positive DM patients that
as compared to 55 anti-Mi2-negative DM controls. The
resence of anti-Mi2 autoantibodies was associated with an
ncreased prevalence of classic Gottron papules and/or sign
nd periungueal erythema as well as a lower risk of cutaneous
lcerations ( p ≤0.05). These antibodies had been associated
ith prominent muscle weakness and higher creatine kinase
CK) levels [22] . Consistent with this, more than half of the
nti-Mi2-positive patients from the French cohort initially
resented with severe muscle weakness (MRC-5 scale
3). Previous case series have reported a low prevalence of
xtramuscular features, including Raynaud phenomenon, ILD,
nd arthritis [22 , 23] . In the French cohort, however, a third
f patients presented with ILD, albeit mostly mild. Arthritis
nd Raynaud phenomenon were observed in only 10% of
nti-Mi2-positive DM patients. Pathological descriptions of 
nti-Mi2-positive DM have reported an increased prevalence 
f primary inflammation (i.e., focal lymphocytic invasion of
yofibers) [12] and, in children, relatively severe pathological
ndings based on a validated juvenile DM biopsy scoring
ystem [24–26] . A systematic review of muscle biopsies
rom the French patients revealed that anti-Mi2-positive
M patients ( n = 14) had increased numbers of diffuse
D68 + dominant inflammatory infiltrates, more necrotic
nd regenerative fibers, and increased sarcolemmal C5b-9
eposition on non-necrotic fibers compared to anti-Mi2-
egative DM controls ( n = 32). Traditionally, anti-Mi2
ntibodies have been associated with a good prognosis
nd low risk of malignancy. Indeed, the presence of these
utoantibodies was even suggested to be an exclusion criteria
or paraneoplastic myositis [27] . However, in the French
















































































































f  cohort, cancer was found in 22% of anti-Mi2 DM patients
within 3 years of diagnosis, with a standardized incidence
ratio (SIR) of 5.1 [3.0–8.6] ( p < 0.001). A better prognosis
and survival rate has been reported in association with
this antibody [22 , 24] . Nonetheless, a relapsing disease was
observed at follow-up in 50% of patients in the French cohort.
Professor Olivier Benveniste presented on the clinical
phenotype of DM patients with autoantibodies recognizing
small ubiquitin-like modifier activating enzyme (SAE).
These autoantibodies are relatively rare, representing only
1–8% of all DM patients. Indeed, only seven case series of
anti-SAE-positive DM patients have been published with a
total of just 66 patients [28–35] . Adding to these, professor
Benveniste presented data on a series of 41 anti-SAE-positive
DM patients collected from among several different
French Internal Medicine or Dermatology departments.
All these patients tested positive for anti-SAE autoantibodies
using the Euroimmun line blot which, compared to
immunoprecipitation, has been shown to have 100%
sensitivity and 99.6% specificity for these autoantibodies [34] .
No marked differences were observed between the already
reported patients and the new French series. These patients
typically present with a classic DM skin rash (i.e., heliotrope
rash and Gottron’s papules) which is refractory to treatment
in more than 50% of the cases. These patients can be
amyopathic (20%) and when muscle weakness is present,
it is generally mild (proximal muscle strength in the 4–5
range) with an average CK level of 216 IU/L. Nevertheless,
swallowing troubles are frequently encountered (40%). ILD is
rare (15% in the French series) and, when present, most often
has a pattern consistent with organizing pneumonia (with
condensations) rather than non-specific interstitial pneumonia.
Finally, concerning associated cancer, the number of patients
reported in the literature and in the French series is currently
too small to draw any definite conclusions. 
Both Drs. Yves Allenbach and Guochun Wang described
the clinical features of patients with autoantibodies
recognizing melanoma differentiation-associated gene (MDA)
5. Speaking first, Dr. Allenbach pointed out that anti-MDA5
autoantibodies were initially found in Japanese DM patients
who were predominantly amyopathic but who frequently had
ILD [36] . Since then, it has been shown that the prevalence
of anti-MDA5 in myositis patients ranges from 4 to 7% in
Europe and North-America and from 15 to 20% in Asia
[37–39] . Anti-MDA5-positive DM occurs mainly in women
(56–88%) [39 , 40] , in the 43–48 years of age range [39 , 41] ,
and has been associated with defined HLA haplotypes in
Asian regions [38 , 42] . Anti-MDA5 autoantibodies delineate a
relatively homogeneous phenotype of DM with predominant
extra-muscular manifestations including a high risk of life-
threatening lung complications in which the signs of myositis
are mild or absent. The phenotype of children with anti-
MDA5-positive DM is similar to that of adult DM, although
the frequency and the severity of the ILD seem to be lower
in children [43] . 
DM associated with anti-MDA5 autoantibodies is a
systemic disease with skin (95–100%), lung (75%), joint40%), and muscle involvement (40%) associated with
onstitutional signs (fever 50%). In addition to the classical
M skin rash, patients present frequently with other
haracteristic skin features including ulcers, palmar papules
r mechanic’s hands [44] . Another characteristic of the
isease is the very high frequency of ILD (50–100%) [39 , 45]
ompared to other DM patients. ILD is frequently rapidly
rogressive [46] explaining the poor survival rate of the
isease (59–75%) [40 , 41] . Moreover, up to two thirds of
he patients have polyarthritis [47] . Of note, even though
nti-MDA5-positive DM is not associated with an increased
isk of malignancy, the disease remains the most severe, in
erm of mortality, compared to all other forms of myositis. 
Among anti-MDA5 positive DM patients, relatively few
ave muscle weakness (0–55%) [40 , 46] and the CK levels
re relatively low (173–912 IU/L) [40 , 41] . Consistent with
his, myopathological features are mild, and only a minority
f the patients have classical DM perifascicular pathology
12 , 48] . Lymphocytic infiltrates are mild and although these
re frequently clustered around vessels, a vasculopathy is
ot morphologically obvious [48] . Interestingly, anti-MDA5-
ositive DM shares the same muscle tissue IFN-signature
ith anti-MDA-negative DM, albeit at lower level [48] . Along
ith the high IFN-I level in the blood of MDA5-positive
atients [49] , this suggests a common pathomechanism in
nti-MDA5-positive DM as well as in other forms of DM. 
Speaking next, Dr. Guochun Wang reminded the audience
hat MDA5 is one of the retinoic acid-inducible gene (RIG)-
ike receptors (RLRs) and that many viruses can trigger
DA5’s activation. Through a complicated procession,
DA5 activation results in the expression of IFN and the
nduction of antiviral effector genes to limit virus replication
nd spread. Thus, MDA5 plays an important role in the
ost’s anti-viral response [50] . Based on this biological role
f MDA5, it has been proposed that anti-MDA5 autoimmunity
s triggered by virus infection and related to IFN expression.
o date, there are several studies confirming that DM patients
ith anti-MDA5 autoantibodies and other subtypes of DM are
trongly associated with increased IFN expression [48 , 51 , 52] .
In the Chinese cohort described by Dr. Wang, the
revalence of anti-MDA5 autoantibodies was 12.9%.
nterestingly, these patients seem to have two clinically
istinct mucocutaneous phenotypes. The first is cutaneous
lceration, occurring in as many as 80%. These ulcers have
 predilection for certain sites – overlying Gottron papules
r Gottron sign on the hand, elbows and/or shoulders. Less
ommonly, these ulcers may occur on sun-exposed sites
uch as arms, chest and back. The second mucocutaneous
eature associated with anti-MDA5 autoantibodies is alopecia.
ortunately, once disease activity has been controlled, this
omplication typically improves relatively quickly. 
Dr. Wang noted that the prevalence and severity of muscle
nvolvement in MDA5-positive DM varies in different reports
36 , 44 , 53 , 54] . As these reports are derived from DM cohorts
n different continents, it is unclear if there is a relation
etween ethnicity and muscle involvement. However, reports
rom the Japanese and Chinese groups both show that
















































































































S  here was a lower rate of clinically apparent myositis in
nti-MDA5-positive DM compared to American and 
uropean cohorts. 
The most significant and potentially life-threatening feature
ssociated with anti-MDA5-positive patients is RP-ILD. In
he Chinese cohort, 78.9% of the patients had RP-ILD during
he disease course [55] . Moreover, a meta-analysis conducted
y Dr. Chen et al. showed that the odds ratio for developing
P-ILD was 20-fold higher in anti-MDA5 positive DM
atients than in DM patients without these autoantibodies
46] . The radiological features of this type of RP-ILD
sually showed perilobular opacities that progressed rapidly
o wide consolidation during the course of the disease. Of
ote, the pathological features of the RP-ILD in anti-MDA5
atients have not been deeply explored. In the few cases
eported, most had a diffuse alveolar damage (DAD) pattern
t autopsy [56] . Pneumomediastinum and/or subcutaneous
mphysema is another severe complication that has been
een in anti-MDA5 patients and these features are associated
ith poor survival [57] . 
Importantly, anti-MDA5-positive patients seem to be
ore susceptible to infection, including severe or fatal
neumocystis jirovecci pneumonia (PJP). In the Chinese IIM
ohort, the occurrence of PJP was 3.4%, and 40% of these
ere from the anti-MDA5-positive group. Both lymphopenia
nd hyperferritinemia are common laboratory features of anti-
DA5 patients. Regarding the outcome of Chinese patients
ith anti-MDA5-positive DM, most had poor response to
lucocorticoid therapy and needed more aggressive treatment.
he 5 year survival rate of the anti-MDA5 patients was only
0.2% in this cohort [58] . 
In summary, Dr. Wang concluded that although the
utaneous and pulmonary features are different and more
evere than seen in other types of DM, anti-MDA5-positive
M should be considered a subtype of DM rather than as a
eparate disease. 
. Pathological criteria for DM 
Professor Jan De Bleecker began by presenting
npublished data from a study evaluating inter-rater variability
n muscle biopsy reading in IIM. Despite the fact that most
xperts in the field acknowledge that muscle biopsy is an
mportant tool in diagnosis and sub-differentiation of the
orms of myositis as well as for differentiating autoimmune
yositis from muscular dystrophies, other degenerative 
ereditary myopathies and toxic myopathies, little data is
vailable on standardization and validation of adult patient
iopsy findings. Two focused European Neuromuscular 
entre (ENMC) workshops led to a consensus on a
ecommended set of minimal stains for IM biopsy evaluation
nd a score sheet assessing individual pathological features
f muscle biopsies [59 , 60] . An international group ( n = 12)
f experts in IM muscle biopsy reading scored 26 muscle
iopsies using a scoring tool that surveyed findings in 4
omains: muscle fiber, inflammatory, vascular and connective
issue [25] . Overall severity of the pathological abnormalitiesere scored on a visual analogue scale (VAS), and a final
iagnosis had to be made from 7 possibilities: DM; PM;
nclusion body myositis (IBM); antisynthetase syndrome 
yositis; IMNM; nonspecific myositis; other. Fleiss’ kappa
or categorical outcomes was calculated and interpreted as:
oor ( ₭ < 0.01); slight ( ₭ 0.01–0.20); fair ( ₭ 0.21–0.40);
oderate ( ₭ 0.41–0.60); substantial ( ₭ 0.61–0.80) or near
erfect ( ₭ 0.81–1.00). 
Inter-rater agreements were often surprisingly low for
ndividual pathological features, even for well-known 
bnormalities (e.g., slight for fiber necrosis and regeneration,
educed capillary density or membrane attack complex (MAC)
taining on capillaries). Agreement was fair for presence of
nflammatory cells invading non-necrotic muscle fibers, the
resence of perivascular inflammatory cells, and the presence
f perimysial inflammatory cells. Moderate agreement was
btained for perifascicular muscle fiber atrophy, perifascicular
uscle fiber necrosis, or the presence of fibers with rimmed
acuoles. Almost perfect agreement was reached for the
resence of perimysial alkaline phosphatase positivity in
onnective tissue. The agreement on the general severity
core was fair. Moderate agreement was also reached for the
nal diagnosis ( ₭= 0.443), a decent inter-rater agreement
iven that 7 categories were offered. Possible reasons for the
oor inter-rater agreements on even routinely assessed biopsy
eatures were discussed along with future plans to improve
he scoring sheet [61] . 
Next, Dr. Ichizo Nishino discussed the pathological
eatures of DM muscle biopsies in a Japanese cohort.
e noted that the type I interferon (IFN) signature in
M muscle was first demonstrated by microarray analysis
62] and that this has been subsequently confirmed in several
eports. Consistent with this, the upregulation of type I
FN pathway genes was observed on RNAseq analysis on
uscle tissue from Japanese DM patients. Among all the
roteins encoded by genes constituting type I IFN signature,
yxovirus resistance protein 1 (MxA) seems to be the most
eliable diagnostic marker for DM [63] . Indeed, its diagnostic
otential was recently tested by an international group and
howed that MxA was expressed in DM muscles but not in
ny of 30 antisynthetase syndrome (AS) cases. Dr. Nishino
as now tested a much larger number of antisynthetase
ases [64] . This revealed that only 3 of 194 AS cases
xpressed MxA in the muscle. This confirms that muscle
xA expression is highly specific to DM and also suggests
hat the pathomechanisms underlying DM are distinct from
hose underlying AS even though the latter entity is often
iagnosed as DM [65] . Dr. Nishino suggested that DM
hould be redefined as a type I interferonopathy and that AS
s a separate disease. 
Dr. Nishino also described a study in which his group
haracterized the myositis-specific autoantibodies present 
n the serum of 98 consecutive DM cases analysed
etween June 2015 and December 2018 and who had
xA-positive muscle pathology. Interestingly, DM-specific 
utoantibodies recognizing TIF1- γ , MDA5, Mi2, NXP2 and
AE were present in all but 3 of these cases, indicating










































































































p  a tight association between DM-specific autoantibodies
and myofiber MxA expression. Dr. Nishino proposed that
these autoantibodies are a biomarker of muscle type I
interferonopathy. 
Of note the prevalence of perifascicular atrophy varied
according to DM-specific autoantibody status in the Japanese
population. This histological feature was present in 91%
of those with anti-Mi2, 45% of those with anti-TIF1- γ
or anti-NXP2, and only 11% of those with anti-MDA5
autoantibodies. 
It has been reported that myofiber MHC-II expression is
more frequent in AS (81.8%) than in DM (23.5%) and that its
perifascicular expression pattern was specifically seen only in
AS but not in DM [66] . Among 194 AS and 95 DM cases in
the Japanese cohort, MHC-II was expressed in 53% and 29%
of cases, respectively. Interestingly, however, perifascicular
MHC-II expression was seen not only in AS cases (36% in
all AS, most common in anti-Jo1 [61%]) but also in DM
cases (14%). This was the case in anti-NXP2-positive DM
(34%) but much less frequent in anti-TIF1- γ (9%), anti-Mi2
(9%) and anti-MDA5 DM (6%). 
Sarcolemmal MAC deposition is considered a pathological
marker indicative of immune-mediated muscle fiber necrosis.
It was seen in 73% of anti-Mi2 DM cases but much less
frequently in other subtypes such as anti-TIF1- γ [24%],
anti-NXP2 [9%] and anti-MDA5 [6%]. This is consistent
with the observation that the percentage of necrotic fibers
and CK levels are highest in anti-Mi2 DM cases and lowest
in anti-MDA5 DM. 
Perimysial connective tissue fragmentation and alkaline
phosphatase expression are reported to be characteristic
pathological features of anti-Jo-1 myopathy [67] . In a
Japanese cohort, perimysial connective tissue fragmentation
was seen in 63% of AS patients but also in 59% of DM
cases – most frequently in anti-Mi2-positive DM (91%).
Likewise, perimysial alkaline phosphatase activity was seen
in 42% of AS and 32% of DM cases, respectively, with the
highest frequency in anti-Mi2-positive DM (91%) among all
DM subtypes. 
Microinfarction was seen in 2.8% of adult and 28.6% of
juvenile DM (JDM) cases, indicating that JDM cases are
at a 10 times higher risk for microinfarction. Interestingly,
none of the microinfarction cases was positive for anti-Mi2
antibodies (although the number of cases was too small to
draw definite conclusions). 
Dr. Nishino concluded by noting that type I IFN
signaling in muscle is tightly associated with the DM-
specific autoantibodies (i.e., those recognizing TIF1- γ ,
MDA5, Mi2, NXP2 and SAE) but not with antisynthetase
autoantibodies (e.g., those recognizing Jo1). Therefore,
DM should be considered as a separate disease than AS
with the former redefined as a type I interferonopathy.
Furthermore, the pathological features of each subtype of
DM seem to be different. Most strikingly, anti-Mi2 DM is
characterized by perimysial pathology, perifascicular atrophy,
sarcolemmal MAC deposition, and is the least associated
with microinfarction. Next, Professor Werner Stenzel discussed pathology
arameters that can be useful to differentiate DM from
ther forms of myopathy. He noted that from a purely
orphological point of view, DM is heterogeneous and that
his fact has long been recognized, discussed, and tried
o be understood in terms of implementing characteristic
iagnostic biopsy-criteria. He suggested that understanding
he pathophysiology of DM could be based on parameters
isible under the microscope or more recently by modern
nalytical methods using muscle biopsy samples such as
issue-based transcriptomics, proteomics, RNA-sequencing,
enomics and combinations of these techniques in the future.
In the following session, Dr. Stenzel discussed the
xperience in Berlin with regard to the association of
ertain muscle biopsy features with different DM-specific
utoantibodies. As muscle involvement is frequently patchy
n anti-MDA5 DM, pre-biopsy localization of most affected
uscle tissue may be especially warranted in these cases.
imilarly, within a biopsy sample, pathological changes may
e confined to a certain area, while the rest of the biopsy
ay look rather minimally affected on H&E stains. However,
taining for MHC class I, CD56, or neonatal myosin can
ighlight focal areas next to affected areas with sparse
erimysial and perivascular cell infiltrates. Importantly, in
nti-MDA5-positive DM, a putative myoprotective mechanism
as been identified by co-expression of iNOS and HSP70 in
hese areas [48] . 
The biopsy features of anti-Mi2-positive DM patients
nclude characteristic atrophic fibers mostly confined to
erifascicular regions and other areas featuring less structured
reas of atrophic fibers admixed with scarce necrotic
yofibers; atrophic fibers are never localized exclusively
n the perifascicular region. Usually, these biopsies show
bundant lymphocytic infiltration, mostly localized to the
erimysium and located around vessels; however, there
s no leukocytoclastic vasculitis. In addition, numerous B
ells, frequently clustered together in perimysial areas often
djacent to larger perimysial vessels, can be identified in
hese biopsies. Perifascicular pathology can be highlighted
y MHC class I staining that shows a characteristic gradient
owards the centrofascicular region and also by stains
nformative about regenerative processes partly featuring the
eri-towards centrofascicular gradient but partly showing a
ore focal and more randomly distributed pattern of positive
taining. MAC is predominantly positive on the sarcolemma
f myofibers and not on the capillaries. 
Anti-TIF1- γ -positive DM cases have distinctive
orphologic features including large areas of atrophic
bers at the edge of numerous fascicles, affecting whole
ascicles, and extending deeply into the center of the
ascicles. Many of these atrophic fibers also have so-called
unched-out vacuoles, which, at variance with the rimmed
acuoles in IBM, do not show violaceous lining by Gömöri
taining, and often harbor cytoplasmic bodies. These areas
lso feature ‘ghost fibers’ with ATP-ase 9.4 (faint or even
bsent staining), and prominent cytochrome oxidase (COX)-
aleness (greyish to pale-blueish discoloration) in combined













































































































pOX- (succinate dehydrogenase) SDH stains. Most strikingly,
hese biopsies show predominant MAC deposits on
apillaries, which is often pronounced fascicle-wise, and
eposits on the sarcolemma may be less prominent. Staining
or MHC class I is strongly positive and often shows a
eri– towards centrofascicular gradient. Professor Stenzel 
mphasized that this combination of different patterns along
ith a positive TIF1- γ autoantibody is highly suggestive of
ancer-associated adult DM, which has also been highlighted
n a larger Japanese study [68] . 
Anti-NXP2-positive DM patients also harbor characteristic 
eatures in their biopsies, which may be summarized
y perifascicular pathology highlighted by MHC-class I
taining, atrophic fibers confined to the perifascicular region,
nd MAC stain on capillaries and also on the sarcolemma.
nti-NXP2 patients can exhibit focal areas of necrotic fibers
imilar to regional ischemic processes, and this is mostly
een in patients with very high CK levels, acute clinical
resentation and predominantly in children. 
Anti-SAE-positive biopsies are not yet available in large-
nough quantities to draw any conclusions for morphological
nalysis. 
Analyzing different subgroups of DM muscle biopsies,
erner Stenzel emphasized that 7 of the most relevant type I
FN signature genes were similarly elevated in a qPCR study
n all subforms of DM and also in DM without any known
utoantibody, highlighting that the type I IFN signature is
 useful unifying pattern for all DM subgroups and can be
sed to differentiate DM from other diseases. 
Dr. Josefine Radke discussed whether performing a
uscle biopsy is necessary to make a diagnosis of DM. She
eminded the audience that IIMs are a heterogeneous group of
ystemic diseases that manifest with muscle inflammation and
eakness as well as elevated muscle enzymes. Extramuscular
anifestation with involvement of different organs, e.g.,
he lung, or the skin is common. The most common type
s DM. Patients typically present with symptoms including
ub-acute to chronic proximal weakness and with a variety
f characteristic skin manifestations. Further laboratory 
nvestigations, including increased serum creatine kinase 
CK) levels and the presence of myositis-specific antibodies
MSA) help to confirm and specify the subtypes. 
Despite the above considerations, Dr. Radke concluded that
 muscle biopsy followed by histological evaluation remains
he gold standard for diagnosing DM, especially since
ultiple clinical presentations may overlap with possible
ifferential diagnoses with similar clinical presentation which
ight be missed. These include rare phenotypes such as IgG4-
elated myositis and brachio-cervical inflammatory myopathy 
BCIM). In addition, histological evaluation of a skeletal
uscle biopsy may also inform about the different subtypes of
M. Lastly, a correct diagnosis may be suggested by muscle
istology in patients with a non-inflammatory myopathy who
appen to have false positive myositis autoantibody testing. 
On the other hand, a muscle biopsy is an invasive
rocedure and complications can occur, which may include a
ematoma or infection at the biopsy site, or complications dueo general anesthesia in children. Therefore, the indication for
 muscle biopsy needs to be critically discussed. Following
n intensive discussion regarding the pro and cons of the
ecessity of a muscle biopsy in DM, most participants
oncluded that in patients with a typical clinical picture and
M-specific autoantibodies, a diagnosis of DM can be made
nd the muscle biopsy may be omitted. In contrast, if the
linical picture is atypical or DM-specific autoantibodies are
bsent or not conclusive, a muscle biopsy is still needed to
ecure the diagnosis of DM. 
. Cancer and DM 
Dr. Lisa Christopher-Stine reviewed evidence regarding 
he association between DM and malignancy. She noted that
mong the different forms of myositis, DM has the highest
isk for an associated cancer, with 10–20% of patients being
iagnosed with cancer-associated myositis (CAM) [69] ,
efined as cancer occurring within two years before the onset
f myositis or no more than three years afterwards [70] . 
The increased risk of cancer in DM varies across cohorts,
ith SIRs in the range of 2.4–6.5 [71] . The salient clinical
nd laboratory features associated with malignancy are
lder age at onset, male sex, more severe skin disease,
levated CRP, and/or elevated ESR [71] . A recently reported
linical feature closely associated with malignancy and found
xclusively in patients with anti-Tif1- γ autoantibodies is
n asymptomatic, well-demarcated, erythematous patch on 
he posterior hard palate. These “ovoid palatal patches” do
ot ulcerate and frequently contain white macular markings
nd a symmetric arcuate configuration across the midline
72] . In contrast to the aforementioned clinical features, DM
atients with ILD, arthritis, and Raynaud’s phenomenon have
 decreased risk of cancer [71] . 
To date, DM-specific autoantibodies anti-Tif1- γ and 
nti-NXP2 have the strongest known link to malignancy. In
ne study of the Hopkins cohort, patients with either one
f these autoantibodies had an increased risk of cancer with
n odds ratio of 3.78 (95% confidence interval 1.33–10.8).
tratification by sex revealed that anti-NXP2 was specifically
ssociated with cancer in males with an odds ratio 5.78 (95%
onfidence interval 1.35–24.7) [8] . A subsequent study of the
opkins cohort confirmed that anti-NXP2-positive patients 
ave increased cancer risk [9] . 
In one Japanese cohort, the frequency of cancer in anti-
AE-positive patients was significantly higher than in the
nti-SAE-negative patients (4/7 vs. 18/143, P < 0.0093)
32] . Although ILD is usually associated with protection
rom cancer, in one study, 5 of 35 (14%) anti-SAE antibody-
ositive patients had both ILD and malignancy [73] . 
Dr. Christopher-Stine next reviewed a conceptual model
f the antitumor response as a trigger of DM, analogous to
ne recently proposed to occur in systemic sclerosis [74] .
ccording to this model, DM autoantigens (especially those
ssociated with cancer) are modified in malignant cells (e.g.,
verexpression, gene mutation, ectopic expression, and/or 
osttranslational modification). These modifications lead to 














































































































D  the development of autoantigen-specific T and/or B cell
antitumor response. Subsequently, cross-reactivity and/or
epitope spreading leads to loss of tolerance against the native
protein, promoting an autoimmune response against healthy
tissues such as muscle and skin [75] . 
Dr. Albert Selva-O’Callaghan elaborated further on
the mechanisms of cancer risk in patients with DM.
Epidemiological evidence has shown that at least one-third of
patients diagnosed with DM develop a malignancy within 3
years after the diagnosis [76 , 77] . Although certain neoplasms
may be overrepresented, any type of cancer can be associated
with DM [78] . The pathogenesis underlying this association
is not well understood, but three mechanisms have been
proposed: molecular mimicry, tumor cell DNA mutations,
and activity of the checkpoint inhibitor pathway. 
Casciola-Rosen et al. found that some antigens were
overexpressed in muscle of DM patients and also in some
types of cancer, such as breast and lung cancer [79] . This
seems to be the case for the Mi2 antigens. T and B cells
target these antigens and generate anti-Mi2 antibodies which
could cross-react between cancer and muscle. This would
lead to the development of inflammatory muscle disease by
means of molecular mimicry. 
Another proposed mechanism is related to DNA mutations
detected in some tumor cells. These mutated genes synthesize
slightly different proteins, which act as neoantigens and
generate a sustained immune response against the tumor that
cross reacts against our own tissues, producing autoimmune
diseases such as DM. In an elegant study, Joseph et al. found
that mutations in the POL3RA gene, which encodes RNA
polymerase III, synthesize a neoantigen that is recognized
by the patient’s immune system and leads to production of
anti-RNA polymerase III, a well-recognized autoantibody
found in patients with cancer-associated systemic sclerosis
[74] . A cross-reactive immune response between the tumor
and normal human tissues was suggested by the authors.
This mechanism has also been postulated in patients with
cancer-associated DM. A recent study found that patients
with anti-TIF1- γ , an autoantibody highly associated with
cancer-associated DM, showed a larger number of gene
changes (mutations and loss of heterozygosity [LOH] in
TIF1 genes) than DM patients testing negative for anti-TIF1-
γ autoantibodies [80] . In these cases, the immune response
against cancer seems to produce two different scenarios: the
strong immune response abates cancer and it disappears, or
the malignancy adapts by means of cancer immunoediting
and LOH, deleting the mutated gene and selecting more
aggressive tumor cells, which leads to the poorest outcome
in these patients. In either of these two cases, the immune
response shifts from cancer (eliminated or transformed) to
tissues expressing high levels of TIF1- γ , mainly muscle
and skin. As the damaged muscle expresses additional
TIF1- γ [80] , a deleterious positive biofeedback effect would
propogate the disease. 
The final proposed mechanism of the cancer-myositis
association involves the checkpoint inhibitor pathway.
PD-1/PD-1L is a well-known physiological inhibitoryathway that downregulates the immune system to allow
elf-tolerance. Blockade of this pathway with the use of
onoclonal antibodies such as ipilimumab or pembrolizumab
nhances the immune response against the tumor and
mproves the outcome in diseases such as melanoma and
on-small-cell lung cancer. The mutational burden and
troma-tumor infiltrating lymphocyte (str-TIL) density are
iomarkers of a good response to checkpoint inhibitors. It has
een suggested that soluble-PD-1L, considered a surrogate
f checkpoint inhibitor activity, is increased in patients with
ancer-associated DM [81] . It remains to be demonstrated that
umors in DM patients show a high mutation burden together
ith high str-TIL density or PD-1/PD-1L expression. If this is
he case, our approach to treatment of the cancer and myositis
ccurring in patients with cancer-associated DM will change.
Next, professor Olivier Boyer reviewed the association
f DM with cancer. He noted that the link between adult
M and cancer had been established by numerous studies
71 , 78 , 82 , 83] and recent meta-analyses [84 , 85] . In contrast,
ancer rarely, if ever, occurs in children with DM. The risk of
ancer in adult DM is strongly correlated with the presence
f autoantibodies, most notably to anti-TIF1- γ autoantibodies
ith a rate of associated malignancy of more than 50%.
IF1- γ is the third member of the TIF1 protein family which
lso includes TIF1- α and TIF1- β [16 , 86] . Interestingly,
IF1- γ is involved in cellular pathways of tumor promotion
75] . Is the autoimmune status in DM a background for
ancer development or, alternatively, may cancer elicit DM? 
In support of the second hypothesis, Professor Boyer
iscussed the model previously reviewed by Dr. Christopher-
tine. Furthermore, along these lines, he presented
reliminary results from his group revealing point mutations
n the TRIM33 gene by next generation sequencing of tumor
NA from a small series of DM patients. 
He next reported on his group’s recent investigations
imed at determining whether a distinct type of anti-TIF1- γ
utoantibody response, different from that seen in juvenile
M, might be associated with cancer among adult DM
atients [87] . For this, his group developed a quantitative anti-
IF1- γ Addressable Laser Bead Immuno-Assay (ALBIA)
hat allows for the determination of autoantibody levels and
sotypes. First, they found that the distribution of autoantibody
sotypes was very different between adult and juvenile DM
atients with anti-TIF1- γ autoantibodies. Whereas the IgG4
sotype was almost always present in children with DM, this
sotype was never found in adult DM patients. The most
triking result of this multicenter French study was that one
nti-TIF1- γ autoantibody isotype, IgG2, was significantly
ssociated with the occurrence of cancer and increased
ortality in adult DM patients. Indeed, high levels of the
gG2 isotype had a 100% positive predictive value of cancer.
ultivariate analysis revealed that age greater than 60 years
nd the presence of anti-TIF1- γ IgG2 were independently
ssociated with mortality. Interestingly, no cancer developed
fter two years in either anti-TIF1- γ IgG2 + or IgG2 −patients,
uggesting that intensive screening for neoplasia in adult
M patients with anti-TIF1- γ autoantibodies may not be















































































































m  equired after 2 years of follow-up. The workshop participants
oncluded that anti-TIF1- γ IgG2 may represent a potential
ew biomarker of cancer and, as such, agreed on the
erspective of conducting a multicenter international study
n this subject. 
. Pathophysiology of DM 
Dr. Janine Lamb (Manchester, UK) reported on genetic
isk factors in DM. The first comprehensive genomewide
ssociation study (GWAS) of DM was conducted by the
yositis Genetics Consortium (MYOGEN). This study of
178 adult- and juvenile-onset individuals of European
ncestry identified the human leukocyte antigen (HLA)
egion as the most significantly associated, but also identified
ssociation with genes implicated in other autoimmune
isorders [88] . A follow up study carried out using the
llumina Immunochip array identified the most significant
ssociation to HLA-B ∗08:01 ( p = 2.46 ×10 −42 , Odds Ratio
OR) 1.9, 95% Confidence Interval (CI) 1.66–2.17) in 879
dult-onset DM, with independent association to HLA-
QB1 ∗04:02 and a significant amino acid association at
LA-DQB1 amino acid position 57 ( p = 8.95 ×10 –14 ) [89] ;
his amino acid also has been reported as a risk factor for
ype 1 diabetes. In 471 cases with juvenile-onset DM, the
ost significant association was to HLA-DRB1 ∗03:01, with
ndependent association to HLA-C ∗02:02, suggesting that the
enetic risk variants underlying juvenile and adult-onset DM
ay differ [89] . 
A recent study reported the role of copy number variation
f the complement C4 gene and C4A deficiency in JDM
90] . The first GWAS in 576 individuals of Japanese ancestry
id not identify genomewide significant association to the
LA region, but did identify association in 33 individuals
ith clinically amyopathic DM to a splicing variant of the
DYF4 gene ( p = 1.5 ×10 −8 , OR 3.87, CI 2.23–6.55) that
reated a truncated WDYF4 isoform [38] . Functional studies
howed that WDYF4 increases NF- ĸ B activity, interacts
ith pattern recognition receptors, causes altered MDA-5
ignalling and increases MDA5-induced apoptosis [38] .
hilst only nominal association to this gene was identified
n 21 clinically amyopathic DM individuals of European
ncestry, this could be explained potentially by differences
n the relative frequency of MDA5 autoantibodies in these
ndividuals between the Japanese and European populations
72% vs. 0% of those tested, respectively). 
Given that myositis autoantibodies define more clinically
omogeneous subgroups, the MYOGEN Consortium has
ecently used genetic data to characterize HLA associations
ithin serology-defined subgroups [91] . For DM specific
utoantibody anti-TIF1- γ ( n = 197), the strongest HLA allele
ssociation reaching study-wide significance ( p < 2.9 ×10 −5 )
s to HLA-DQB1 ∗02 ( p = 2.34 ×10 −11 , OR 2.49, CI 1.88–
.31). When the cohort is stratified into adult and juvenile-
nset patients, anti-TIF1- γ DM ( n = 91) shows association
o HLA-DQB1 ∗02:02 ( p = 2.96 ×10 −5 ), whereas anti-TIF1- γ
DM ( n = 106) shows association to HLA-DQB1 ∗02:01 p = 3.70 ×10 −5 ), part of the 8.1 ancestral haplotype. These
ifferent genetic associations in adult and juvenile-onset anti-
IF1- γ positive patients may indicate different underlying
tiology. For the anti-Mi2 subgroup ( n = 104), the strongest
ssociation is to HLA-DRB1 ∗07:01 ( p = 4.92 ×10 −13 , OR
.47, CI 3.48–8.77), with trends in the same direction for both
dult- and juvenile-onset. For anti-SAE ( n = 31), significant
ssociation was observed to HLA-DQB1 amino acid position
7 (omnibus p = 2.66 ×10 −6 ), but not to any classical HLA
lleles. DM-specific autoantibodies anti-NXP2 ( n = 93) and
nti-MDA5 ( n = 35) did not show any association reaching
tudy-wide significance. Altogether, these data demonstrate 
hat DM autoantibody subgroups have different HLA allele
nd amino acid associations, and that these associations may
e stronger than for clinically defined subgroups. 
Dr. Yves Allenbach discussed mechanisms of myofiber
njury in DM. He discussed the fact that myopathological
nalysis shows that (i) muscle fibers are atrophic, (ii) atrophic
bers are clustered in perifascicular areas and (iii) myofibers
ave evidence of mitochondrial damage [92] . 
The other pathological feature involves the vascular
omain with a vasculopathy characterized by the presence
f perivascular inflammatory infiltrates, capillary loss,
ndothelial complement deposits and undulating tubules 
ithin the endothelial cells (electronic microscopy). 
The interferon (IFN) pathway plays a key role in both
uscle fibers and vascular injuries. The IFN levels and
FN signature scores are increased in the blood of DM
nd are correlated with the disease activity [93] . In muscle
issues IFN stimulated genes are upregulated, especially in
he perifascicular areas [62 , 94] . IFN related proteins are also
etected in muscle fibers in perifascicular areas and their
etection is now considered to be a potential DM diagnostic
iomarker [63 , 95] . In vitro studies showed that IFN impairs
yoblast differentiation and induces myotubes atrophy 
96 , 97] . Finally, IFN also induces mitochondrial dysfunction,
ediated by ROS, contributing to poor exercise capacity [93] .
The observation that some inherited interferonopathies, 
haracterized by defective regulation of IFN, have a
evere vasculopathy (stimulator of IFN genes-associated 
asculopathy with onset in infancy: SAVI) [98] strongly
uggests the pathological role of IFN on endothelial cells.
n DM muscle samples there is a correlation between the
ascular damage and the IFN levels [99] and there is also
 correlation between IFN stimulated genes or IFN related
roteins with related angiogenesis genes and proteins [97] .
n vitro, IFN impairs endothelial cell angiogenesis [97] .
ogether these data highlight the IFN pathogenic role on the
ascular compartment. 
Muscle injury may be also induced by hypoxia. A clue
egarding this mechanism can be found in the case of
ivedoid vasculopathy, a very rare condition characterized 
y a thrombo-occlusive vasculopathy of superficial dermal
icro-vessels (purpura, livedo and ulcerations) due to
hrombophilia. This condition may also affect the muscle
hen it causes a severe vasculopathy leading to perifascicular
yofiber damage [100] . This observation suggests that the












































































































aperifascicular region is especially sensitive to ischemic
insult. In addition, in vitro hypoxia induces IFN-related
protein expression and IFN secretion by myotubes [101] .
Taken together, these findings suggest a key role for IFN
in the pathophysiology of DM. Accordingly, recent clinical
data suggest that IFN-pathway inhibition using Janus-
Kinase inhibitors may improve refractory DM patients
[97] . 
Dr. Manabu Fujimoto next gave an overview of animal
models of myositis. Although no animal models of DM
have been established, there are many animal models of
autoimmune myositis. The classical murine model is well
known as experimental autoimmune myositis (EAM) [102] .
EAM is induced by immunizations of muscle homogenate
or partially purified myosin with complete Freund’s adjuvant
(CFA). However, the only susceptible strain is the SJL mouse
that has a mutant Dysferlin gene. Therefore, improved models
have been reported. Allenbach and colleagues reported a
highly reproducible EAM model in Balb/c or C57BL/6
mice that were immunized repeatedly once a week for 3
weeks with 1 mg purified myosin with CFA [103] . Kohsaka
and colleagues also reported that immunization of skeletal
C-protein, a myosin-binding major immunogenic protein in
the myosin fraction induced myositis in C57Bl/6 mice (C
protein-induced myositis; CIM) [104] . This CIM model is
inducible in B6 mice. Nonetheless, CIM is characterized by
CD8 T cells-mediated muscle fiber-injury, suggesting that
CIM is more representative of PM than DM. Moreover, these
proteins are different from antigens targeted by myositis-
specific autoantibodies in human myositis. 
As for antisynthetase syndrome, mice immunized with the
Jo-1 antigen, histidyl-tRNA synthetase, have been reported
to develop myositis and lung disease in congenital B6 mice
[105] . Also, a recent study by Boyer et al. demonstrated
that IgG transfer from IMNM patients with anti-SRP or
anti-HMGCR autoantibodies can cause the disease in mice
[106] . He concluded that developing experimental DM
models related to DM-specific autoantigens, such as TIF1- γ
proteins, would be beneficial to investigate the pathogenesis
of the human disease. 
Dr. Fujimoto also gave an overview on mechanisms
of skin damage in DM. Despite the characteristic and
distinguishable clinical manifestation, the histopathological
findings of cutaneous eruptions are unspecific and similar
to those in lupus. For example, liquefaction degeneration of
basal keratinocytes, dermal mucin deposition, perivascular
mononuclear cell infiltration, and vascular injury are observed
to varying degrees. Like lupus, molecular mechanisms of
skin damage in DM are likely to be related to type I IFNs
as the increased expression of type I IFN-inducible genes
have been reported [107 , 108] . However, considering the
clinical heterogeneity across different autoantibody groups,
the histopathology would also have to be evaluated based
on autoantibody profiles. He presented preliminary data that
histopathological features as well as type I IFN-inducible
gene expression are distinct for each myositis-specific
autoantibody. . Juvenile manifestations of DM and inherited 
nterferonopathies 
Professor Lucy Wedderburn reviewed the recent advances
n juvenile DM, with a focus on so called endotypes of
isease, their MSA associations and how they relate to
athological features seen in muscle biopsy tissue. In most
arge cohorts of juvenile onset myositis, including the
K Juvenile DM Cohort and Biomarker Study (JDCBS)
109] approximately 65% of children have a detectable
SA [110] . The prevalence of the different MSAs differs
n childhood onset myositis from adult onset IIM [110 , 111]
ith the most common MSAs in JDM cases being TIF1-
( ∼20–25%) and NXP2 (18–20%), while Jo-1, MDA-5
nd Mi2 MSAs are relatively rare in children. A recent
arge UK study has suggested that as MSAs are not
etectable in JSLE or juvenile arthritis, testing of MSAs
ight be useful as part of early diagnostic work up [111] ;
owever, as yet, data are lacking on whether MSAs may be
ound in the monogenic interferonopathies, such as chronic
typical neutrophilic dermatosis with lipodystrophy and
levated temperature (CANDLE) and SAVI syndromes in
hildren, which may be a diagnostic challenge in younger
atients. 
Clinical associations with some specific MSAs are well
ocumented in JDM. Interestingly age at onset also seems to
lay a role in such associations, with one clear example being
alcinosis which is associated with a positive NXP2 MSA
ut also closely correlated with age of onset of disease [112] .
n contrast the TIF1- γ autoantibody appears to be associated
ith risk of cancer in adults but not in children and a recent
tudy of the isotype of TIF1- γ autoantibodies in adults and
hildren suggests that the cancer risk may associate with
pecific isotype of anti-TIF1- γ autoantibodies [87] . A recent
enetic analysis also suggests that unlike previous data for
ther MSAs, the HLA genetic associations for adult and
aediatric onset cases of TIF1- γ positive IIM may also differ
113] . Together these data suggest that immune changes with
ge have differential influences on the specific autoimmune
esponses to autoantigens in IIM. 
The UK group have shown that the MSA data when
ombined with quantitative histopathological score data
easuring severity features on quadriceps muscle biopsy
issue in JDM [25 , 26] provides prognostic value in predicting
isease course and how quickly treatment can be tapered or
topped [24] . In a recent study which included a detailed
valuation of 101 JDM biopsies the UK group has shown
hat severity of biopsy features is significantly different
n different MSA groups with Mi2 positive cases having
lassic, severe features, MDA-5 positive cases having mild or
inimal pathological changes. However, both the anti-TIF1- γ
nd anti-NXP2 positive groups were heterogeneous in terms
f severity and features on biopsy [114] . Interestingly the
egree of IFN driven expression of MxA protein in muscle
iopsies was also found to be differentially expressed in
ifferent MSA groups as well as correlating with weakness
s measured by the CMAS clinical score [115] . 















































































































m  Dr. Cyril Gitiaux presented on the topic of acquired
nterferonopathies associated with skin lesions . He reminded
he audience that juvenile IIMs, including juvenile DM
nd, less frequently, juvenile overlap myositis, are
ighly heterogeneous diseases characterized by multiple
ombinations of clinical, biological and histopathological 
atterns challenging the need for reliable and minimally
nvasive biomarkers of short/long-term outcome, disease
ctivity and response to treatment [116] . Juvenile IIMs are
ostly viewed as non-Mendelian disorders, with disease
usceptibility being linked to the HLA locus as in other
utoimmune diseases [89] . A very rare condition, CANDLE,
ay mimic juvenile DM with early onset, similar cutaneous
ash, myositis and calcinosis. This condition is linked to
utations in genes encoding proteasome components, thus
eading to proteasome malfunction, disruption of proteostasis
nd dysregulation of IFN signaling [117] . A working
ypothesis is that juvenile DM is associated with a type 1
FN upregulation triggered by one environmental stimulus,
argeting a genetically susceptible child. The upregulation
f type 1 IFN is associated with two major pathologic
eatures in muscle tissue: (i) multifocal capillary loss and
ii) perifascicular atrophy. The exact chain of events leading
o loss of blood capillaries and to perifascicular atrophy
emains unknown. Mendelian type 1 interferonopathies are a
aradigm of type1 IFN upregulation and are characterized by
isturbance of the homeostatic control of these IFN-mediated
mmune responses. They are usually present in early life and
ay mimic congenital infection or be mistaken for sporadic
utoimmune diseases such as SLE or JDM [118] . Most
articularly, SAVI, due to TMEM173 gain of function (GOF)
utation, can demonstrate severe ILD and skin vasculitis
eminiscent of MDA5 + JDM phenotype [98] . However,
uscle involvement has not been described so far as a
rominent feature in the Mendelian type 1 interferonopathies.
Biological research conducted mainly in JDM have
emonstrated that type1 IFN upregulation plays an important
ole in the immunopathogenesis of JDM [119–121] . The
ype 1 IFN (IFN-I) signature is detectable in muscle fibers,
yogenic precursor cells (MPCs), and muscle endothelial
ells. Transcriptomic analysis performed in myoblasts
solated from JDM muscles showed a strong IFN-I signature.
ndothelial cells in JDM muscle downregulate genes
elated to vessel development, cell adhesion and migration,
hich are essential for angiogenesis. Downregulation of
hese genes, in addition to the production of angiostatic
ytokines/chemokines, are likely key events in the
evelopment of the vasculopathy seen in juvenile DM.
urthermore, juvenile DM-derived MPCs displayed an
fficient pro-angiogenic activity that triggered capillary 
longation and lumenization. IFN-I triggered pro-angiogenic 
ignature and properties in normal MPCs in vitro, suggesting
n IFN-I pathway through which MPCs may stimulate
ascular remodeling and trigger muscle recovery in JDM
99] . An increased level of interferon-stimulated gene (ISG)
xpression in peripheral blood and IFN α measurement by
igital ELISA, even at very low concentrations, are usefulor diagnostic screening for juvenile myositis and may allow
herapeutic stratification and/or monitoring of therapeutic 
esponses [120] . Treatments targeting the IFN pathway are
eginning to be used in small numbers of patients with
nterferonopathies. In particular, the JAK inhibitors are
merging as a potentially important therapeutic strategy for
DM [122] . 
. Treatment in DM 
Professor Ingrid Lundberg reminded attendees that there
ave been very few controlled trials in patients with IIMs
n general and that in DM, there are no consensus-based
reatment guidelines or recommendations. Thus, available 
reatment recommendations are mainly based on case series
nd expert opinion. 
As a general principle for treatment of patients with
M, pharmacological treatment should be combined 
ith exercise as proposed by Oddis and Aggarwal in
 recent review on treatment of DM and PM [123] .
he authors propose an algorithm for pharmacological 
reatment with glucocorticoids in combination with either
ethotrexate or azathioprine as first-line therapy. As second-
ine therapy, mycophenolate mofetil (MMF), tacrolimus or
iclosporin, or combination therapy such as azathioprine
nd methotrexate may be considered. Third-line therapies
nclude rituximab, cyclophosphamide, repository corticotropin 
njection (RCI) or other experimental biologic agents.
ntravenous immunoglobulin (IVIG) can be used alone as a
rst-line, second-line or third-line therapy or as a concomitant
herapy with any drug depending on clinical phenotype and
omorbidities. 
More specifically treatment recommendations for patients 
ith DM should include use of sunscreens and local therapies
ncluding topical steroids, intralesional steroids or topical
acrolimus. In one of the few controlled trials in DM, three
onths of treatment with high dose IVIG was superior
o placebo concerning improvement of muscle strength
ccording to the MRC scale and a neuromuscular symptom
core [124] . Also, the skin rash improved in 8 patients.
owever, this was a small study including only 15 patients
ith refractory DM and, although convincing data, the results
ave not yet been replicated. 
Concerning biological treatment, a post-hoc analysis of
he rituximab in myositis (RIM) trial, a placebo-controlled
rial in PM and DM, demonstrated improvement of the skin
core with a change in skin activity in a VAS Score from
.20 ±2.46 to 1.72 ±2.09 [125] . Furthermore, the frequency
f any DM rash decreased from 89% (64/72) to 76% (51/67)
 p = 0.047) after 36 weeks. 
In a randomized placebo-controlled pilot study in DM,
rednisone was combined with etanercept or placebo and
hen followed by a forced prednisone taper [126] . At the end
f the 24-week trial, the average daily prednisone dose in
he etanercept arm was 1.2 mg whereas it was 29.2 mg in the
lacebo arm. None of the patients in the placebo group ( n = 5)
anaged to stop steroid treatment after 24 weeks, whereas













































































































s  5/11 patients in the etanercept arm could be weaned off
prednisone suggesting a steroid-sparing effect of etanercept.
These findings need to be confirmed in a larger trial. 
The only FDA approved drug for myositis, repository
corticotropin injection (RCI), H.P. Actar gel, was recently
demonstrated to have beneficial effect on disease activity in
refractory PM and DM patients in a small 24-week pilot
study. Among the patients with significant DM-related skin
rash, 4 of 5 improved in the cutaneous VAS score of the
Myositis Disease Activity Assessment Tool (MDAAT) by
88% [127] . 
Although there are some promising data on
pharmacological treatment effects in patients with DM
[97] , large controlled trials are clearly needed. Furthermore,
some patients are still resistant to available treatment;
therefore, new therapies are needed and increased knowledge
about molecular disease mechanisms will be important. 
Dr. Victoria Werth next presented on skin outcome
measures for DM trials. She discussed the need for
independent critical evaluation of skin manifestations of
DM with reliable and validated measure of skin disease
severity. This requires a precise outcome measure that is
reliable, consistent with high inter- and intra-rater reliability,
that also has validity and sensitivity. DM clinical trials and
patient-focused evidence-based medicine requires such a
validated disease severity tool. 
The cutaneous DM disease area and severity index
(CDASI) was developed to systematically assess the extent
of cutaneous disease in patients with DM and to allow for
capturing responsiveness. Content validity was developed
through discussion with investigators, clinicians, and patients.
Construct validity was evaluated by demonstrating agreement
between the CDASI and the cutaneous assessment tool (CAT)
[128] . There were iterative changes in the instrument based
on these discussions, leading to a second slightly simpler
version2 that performed as well as the initial CDASI [129] .
The goal was an instrument that was quick to use, had high
inter-rater and intra-rater reliability, and would describe a few
clear signs that allowed grading of disease severity. Damage
and activity were scored separately to avoid the paradoxical
stability of a combined score, where activity can decrease
as damage increases. The disease attributes are scored in 15
anatomic sites in terms of the degree of erythema, scale, and
erosions/ulceration. Damage is evaluated by the presence of
poikiloderma, defined as dyspigmentation or telangiectasias,
and calcinosis. The worst area for each attribute in a given
body area is scored, as determining the predominant color or
other characteristic for an area can often be difficult, and%
area is even more difficult. Gottron’s sign/papules, hair loss,
and proximal nailfold changes are scored separately. 
Next to the CDASI there are two other skin outcome
measures developed for DM, the CAT [130 , 131] , and the
Dermatomyositis Skin Severity Index (DSSI). The CDASI
and CAT have been compared in several validation studies,
and the CDASI has higher inter-rater and intra-rater reliability
on formal testing, as well as lower SRM values [128 , 132] .
The CAT requires the skin findings to totally resolve in ordero capture change, making it hard to capture meaningful
hange in the context of a trial. The DSSI is based on body
urface area. Since DM can be on small surface areas, like
he hands, but cause significant activity in these smaller
ocations, the DSSI does not capture the important changes. 
The CDASI is able to capture nuanced, but important,
hanges in the skin, and there is a linear correlation between
DASI activity and patient’s quality of life (QoL), as
easured by the Skindex [133] . In addition, a meaningful
hange in CDASI based on the patients meaningful change
n QoL (MCID) has been defined [134] , and studies based
n even smaller changes in CDASI have demonstrated
eaningful improvement in QoL, including itch and pain
135] . Previous studies based on the change in the physician
isual analogue scale (VAS) determined a meaningful
mprovement from a clinical perspective as a five-point
hange in CDASI [136] . Using the patient perspective to
etermine meaningful change from a QoL perspective, for
hose with a threshold CDASI-A score range of > 14, a 40%
hange or delta decrease in CDASI of 10 in CDASI-A score
s associated with a meaningful change in QoL [134] . 
Validation of the CDASI has been extended to adult
nd pediatric rheumatologists, while neurologists had more
ariation and thus lower inter-rater reliability [137 , 138] . The
DASI is a reliable instrument for use by dermatologists and
heumatologists that are trained in its use, while the data is
ot as robust for neurologists. 
CDASI activity correlates with a number of blood and
kin biomarkers. One study showed the serum IFN- β linearly
orrelated with CDASI activity, and those with a CDASI
ctivity score of ≥12 had higher IFN- β serum levels relative
o those with mild disease [93] . The change in a 10-gene
FN signature correlated with the change in CDASI. 
The CDASI was used as a primary outcome for a phase
 double-blind placebo-controlled trial of a nonpsychoactive
annabinoid, lenabasum [139] . It was able to demonstrate
ignificant improvement in the skin in a short trial that has
ow led to a phase 3 global trial. Many patient-reported
utcomes correlated with the improvement seen in the
DASI. 
Professor Jirˇí Vencovský next discussed muscle outcome
easures for use in clinical trials. He noted that a preliminary
ore set of disease outcome measures for use in clinical trials
n IIMs was proposed in 2001 [140] . The six core set activity
omains that were recommended for inclusion in all myositis
linical trials were patients´ and physician’s global assessment
f disease activity, muscle strength, physical function,
aboratory evaluation, and assessment of extra-skeletal muscle
nvolvement. The degree of change in each core set measure
hat is clinically meaningful was defined [141] . Consensus
efinition of improvement required 3 of any 6 of the core
et measures improved by > 20%, with no more than 2
orse by > 25% (which could not include manual muscle
esting to assess strength) [142] . The criteria were considered
reliminary, because they were not prospectively validated. It
as acknowledged that these criteria had several limitations,
uch as equal weight applied to each core set measure, lack of

















































































































i  uantitative or continuous outcome, and ceiling effect in some
ore set measures. New improvement criteria were released
n 2017. They use weighted assessment of core set measures
eflecting the importance of contribution of each measure
o disease improvement [143 , 144] . The highest weight is
iven to improvement in muscle weakness, followed by
mprovement in global disease activity assessed by physician,
xtramuscular manifestations, global disease activity by
atient, physical function, and muscle enzymes. The latter
arameter is weighted least reflecting low association between
nzyme level change and clinical improvement in some cases.
he criteria provide continuous results and generate a total
mprovement score (on a scale of 0–100). Change can be also
ategorized into minimal, moderate and major improvement
ased on the fulfilment of thresholds. The criteria are
ecommended to be used in all clinical trials in myositis. 
Measurement of muscle weakness or muscle performance
s considered the most important for evaluation of patients
ith myositis. Manual muscle testing (MMT) of proximal
uscle groups or a total MMT score involving proximal,
istal and axial muscles, as well as abbreviated unilateral
MT of 8 muscle groups (MMT-8) have been preliminary
alidated using 0–10 MMT scale [145] . The expanded 0–10
cale is thought to enhance the sensitivity of strength testing.
MT-8, which includes neck flexors, deltoids, biceps, wrist
xtensors, gluteus maximus and medius, quadriceps and
nkle dorsiflexors, performed as well as or better than total
MT and is recommended for use in therapeutical trials.
MT-8 takes less time and requires less patient effort
han other MMTs and is therefore suitable for longitudinal
ollow-up. 
Another possibility is to test muscle endurance. This is
urrently done using the functional index 2 (FI-2) [146] in
hich dynamic repetitive muscle function (DRMF) is tested.
atients perform as many repetitions of each muscle group
s they can, or they stop when reaching maximal number
f repetitions. A percentage of maximum is calculated for
ach task and a sum on different muscle groups provides the
nal scoring. Recently, muscle endurance deficits have been
escribed despite normal manual muscle testing scores [147] .
uscle endurance testing may therefore identify muscle
mpairment inadequately described by MMT, particularly in
atients with high MMT scores [148] . Another recent study
howed that patients with adult PM and DM might be more
imited in DRMF than in isometric muscle strength, again
ointing out the importance of assessing dynamic muscle
unction in addition to the MMT-8 [149] . 
An attempt to improve performance in measurement
f muscle impairment combines MMT-8 with 3-items of
hildhood Myositis Assessment Scale (CMAS) and is thus
ore comprehensive than the former and more feasible than
he latter [150] . The tool (hMC) possesses good measurement
roperties but needs further testing. 
Another, more simple possibility to evaluate muscle
ctivity and its change is the repeated use of the visual
nalogue scale for muscle disease activity which is part of
he MDAAT developed by IMACS [151] , in which patientscore presence of clinical features or symptoms within the
revious 4 weeks that are due to active disease. Similarly, in
nother IMACS tool, muscle damage is measured based on
ombined consideration of the presence of muscle atrophy,
uscle weakness not attributable to active muscle disease,
ecrease in aerobic exercise capacity, low serum creatinine,
nd if available, muscle atrophy assessed by radiographic
ethods [151] . 
Recently, there has been a proposal for a candidate core-
et of fitness and strength tests for patients with childhood or
dult IIMs. It includes treadmill exercise stress test (modified
ruce protocol), incremental cycle ergometer test, 6 min walk
est (6MWT), handgrip strength, MMT, CMAS in children,
nd FI-2 in adults [152] . 
Laboratory biomarker tool measures serum activities of
t least 2 of the 4 muscle-associated enzymes including
reatine kinase (CK), the transaminases (ALT, AST), lactate
ehydrogenase (LD) and aldolase. The most abnormal serum
uscle enzyme value at baseline is used for longitudinal
ollow up [143] . 
Isometric dynamometry provides a quantitative measure 
esting (QMT) that might be sensitive in detecting small
hanges in strength as well as mild weakness that might
ot be detected by MMT [153] . There are many different
nstruments to measure quantitative muscle strength. The
erson administering the test must be trained. Like other
easures of strength, QMT does not discriminate between
ctivity and damage. There is almost no validation in patients
ith myositis [154] . 
Hand held dynamometry (HHD) correlation with MMT-
 has not been found satisfactory, suggesting different
onstruct measurement [155] . HHD could be recommended
o evaluate isometric muscle strength of single muscle groups
n people with myositis if the following important aspects
re considered: examiners are experienced and trained in
uscle testing, a standardized protocol is followed, a belt to
tabilize examiner or the device is used, and the average of
t least two measures is applied. 
Home accelerometers emerge as new tools to measure
uscle performance in patients with myositis [156] .
umerous variables, such as average daily step count
nd acceleration vector magnitude, can be used to describe
he intensity, duration and types of activity. The tool
s practical, objective, provides continuous longitudinal 
onitoring and carries lack of cognitive input from patient
r examiner. However, there is a need for standardization
nd interpretation [154] . 
Muscle imaging by magnetic resonance (MRI)
emonstrates both inflammatory and post-inflammatory 
hanges in the muscles and surrounding soft tissue. In
atients with established diagnosis MRI can help to
etermine whether clinical muscle weakness is based on
hronic muscle damage or relapse of active disease [157] .
he characteristic MRI findings in patients with DM are high
ignal intensities in subcutaneous tissue and fascial areas,
eripheral distribution and honeycomb pattern [158] . There
s no standardized protocol for evaluation of MRI in patients













































































































a  with myositis. There is a need to define the exact parameters,
anatomical localizations, precise MR imaging techniques and
a potential to change to be used in the future scoring systems
[159] . 
Dr. Lisa Christopher Stine outlined potential future DM
treatment trials. She raised some important issues to consider
when thinking about trial design, including whether patients
with skin-dominant disease should be combined with muscle-
dominant DM patient groups. Similarly, she raised the issue
of whether patients with ILD should be excluded from
trials. Next, she discussed trial design concepts, including
whether a placebo group was always needed or whether
a crossover design could be employed in most trials, thus
providing all patients with the ability to have exposure
to the investigational product. Finally, outcome measures
including patient reported outcome measures (PROMs) were
reviewed. 
For cutaneous disease in DM, possible future options may
include subcutaneous immunoglobulin, JAK kinase inhibitors
such as tofacitinib or ruxolitinib, or tocilizumab, all in
current clinical trials [160] . Additional agents currently being
investigated for DM include belimumab targeting BAFF
[clinical trials.gov] and PF-06823859, a monoclonal antibody
against IFN- β [clinical trials.gov] where the predominant
outcome measured is the validated CDASI; however patients
with muscle diseases are not excluded and muscle strength
is captured throughout the trial. [clinical trials.gov]. 
The final product discussed was Lenabasum
(formerly anabasum), a non-psychoactive endocannabinoid
receptor agonist. This product is a first-in-class non-
immunosuppressive, synthetic, oral preferential CB2 agonist
(targets endogenous CB2 receptors on activated immune
cells) that triggers resolution of innate immune responses and
reduces cytokine production by peripheral blood mononuclear
cells from DM patients. The phase 2 trial was an NIH
funded 16-week placebo-controlled, randomized trial for 22
cutaneous-predominant DM to investigate safety, tolerability,
and efficacy. [clinicaltrials.gov] Inclusion criteria included
a (CDASI) activity score ≥ 14, minimal active muscle
involvement, failure or intolerance to hydroxychloroquine,
and stable DM medications including immunosuppressants.
The primary outcomes were the number of participants with
treatment emergent adverse events as a measure of safety and
tolerability at 16 week and change in CDASI scores from
baseline at 12 weeks. Results of the trial were promising
with all participants completing the trial. Trial subjects had
clinically meaningful improvement in CDASI activity scores
with mean reduction ≥ 5 points at all visits after 4 weeks.
Improvement had statistical significance at end of study that
first became apparent after 4 weeks. Lenabasum provided
greater improvement than placebo in CDAI damage index,
patient-reported global skin disease and overall disease
assessments, skin symptoms including photosensitivity and
itch, fatigue, sleep, pain interference with activities, pain,
and physical function. There were no serious, severe or
unexpected adverse events (AEs) related to lenabasum and
tolerability of lenabasum was excellent. Further evaluation ofhis compound in the treatment of DM is now underway in
 Phase 3 global trial. 
. Autoantibody detection 
Livia Casciola-Rosen discussed assays to detect DM
utoantibodies. She presented data summarizing the
xperience of her lab with these assays, noting that the
ab’s focus is on the research use of these tests rather than
linical utility. That is, the assays are designed to read
ut each antibody type with rigorously defined specificity,
ith the recognition that they are not necessarily readily
menable to clinical implementation. Their assay of choice
s immunoprecipitation (IP)-based, because it involves
ecognition of the full-length, non-denatured form of the
ntigen. Assays to detect Mi2, SAE1, MDA5, NXP2 and
MScl (noting that this last antibody is not DM-specific)
ere described and data presented. For these, IP of 35S-
ethionine-labeled protein generated by in vitro transcription
nd translation (IVTT) from the relevant full-length human
NA is used as input for the IPs. The IPs are electrophoresed
n SDS-PAGE gels and visualized by autoradiography
44 , 53] . Since they first reported on the use of this assay
n 2001 (a report of PMS1 antibodies in myositis patients)
161] , the lab has worked with > 70 different kinds of IVTT
roducts as input for IPs, with cohort sizes ranging from 2
original description) to ∼900. For anti-TIF1- γ autoantibody
etection, the preferred assay involves transient transfection
f FLAG-tagged TIF1- γ into cultured cells. The resulting
ysates have TIF1- γ overexpressed ( ∼30–50 fold), and are
sed as input for the IPs, with detection by immunoblotting
sing commercial antibodies against the FLAG tag or TIF1- γ
ith similar results [8] . 
The Johns Hopkins Rheumatology’s NIH P30-funded
heumatic Diseases Research Core Center invested in a
uroIMMUN platform recently and has used this to screen
 cohort of 261 well-characterized DM plasma samples (a
ollaboration with Dave Fiorentino, Stanford University) by
ine blot (LB) using the myositis panel (16 specificities/strip).
ince data using the Rosen lab’s assays were available with
hese samples for the DM specificities, this information
as compared for autoantibodies recognizing MDA5, Mi2,
AE1, NXP2, PMScl and TIF1- γ . Of note, anti-Jo1 antibody
tatus was available for all samples using the INOVA ELISA
it, with overall excellent concordance of LB and ELISA
ata. Where available, a third assay was used to readout
utoantibodies (MBL ELISA used for anti-Mi2, -MDA5
nd -TIF1- γ autoantibodies). Readouts for autoantibodies
gainst Mi2, SAE1 and MDA5 aligned fairly well amongst
ll assays. Agreement between IVTT IP and LB data from
nti-NXP2 autoantibodies was not as good, and there were
ignificant discrepancies for the anti-PMScl and anti-TIF1- γ
utoantibody readouts. Assigning correct TIF1 γ antibody
tatus is of high importance, given its frequency amongst DM
atients and its association with cancer. IVTT IP detected
ubstantially more anti-TIF1- γ -positive samples than the LB
ssay (41% vs. 15%). It is noteworthy that the third assay















































































































tsed to test for anti-TIF1- γ autoantibodies (MBL ELISA)
etected the same additional samples that IVTT IP read out
s being positive, as well as several extra samples, to give
0% positivity for these antibodies in the cohort. 
Data presented in this talk highlighted the urgent need
or standard adoption of carefully validated platforms to
etect these antibodies. Incorrect/missed antibodies affect
he clinical phenotyping correlations that are made in cohort
tudies of these antibodies. This, in turn, impacts clinical
tility and relevance for making an accurate diagnosis. 
Dr. Jan Damoiseaux presented next on standardization
f autoantibody detection methods. He noted that a
tandard preparation to maximize compatibility and enabling
niformity of measuring results of autoantibody testing for
utoimmune diseases is a major challenge. The underlying
roblem is the high variability in the composition of the
utoantibody repertoire within and between individuals. 
s a consequence, samples may react differently in
istinct immunoassays. Most international initiatives on the
reparation of standards utilize plasmapheresis material from
 single patient. By definition, this is never representative for
he whole patient population and, partly because of this, the
ltimate goal of standardization has not yet been met. 
Harmonization, i.e., the adjustment of differences among
easurements, methods, and procedures by recommendations 
nd/or guidelines to improve compatibility, might be the
ighest achievable goal. Harmonization can be obtained at
everal levels of autoantibody testing. First of all, requesting
f the autoantibody tests by the clinician can be guided by
ell-defined clinical manifestations. Such a gating-strategy 
revents testing of patients with a low pre-test probability
nd, as a consequence, a relatively high rate of false-positive
esults (i.e., low specificity). Second, the laboratory specialist
as to choose the most optimal testing system/algorithm.
n case of DM, immunoprecipitation is considered the gold
tandard method. However, immunoprecipitation is not a
tandard method and is not readily available in most routine
iagnostic laboratories. Alternative immunoassays, like line-
r dot-immunoassays, are limited in the availability of
ppropriate clinical evaluations [162] . Although it is evident
hat the HEp-2 indirect immunofluorescent test (IIFT) is not
n optimal screening test for IIMs, the HEp-2 IIFT pattern
ould be used to support the identified antigen-specificity
f the DM-specific autoantibody [163] . The third level
f harmonization involves the way test-results are being
eported by the laboratory specialist to the clinician. For
ome DM-specific autoantibodies there exist two antigenic
ntities: Mi2 α and Mi2 β, and SAE-1 vs. SAE-2. Evidently,
est characteristics will differ for both entities and, therefore,
t should be specified to which antigen(s) the autoantibodies
re reactive. Low-, medium-, and high-positive results will
lso have distinct test characteristics and this can best be
nderscored by reporting in likelihood ratios for test-result
ntervals [164] . Fourth, the test-results obtained should be
nterpreted by the clinician in the context of the clinical
anifestations of the patients. In particular if test-results
re reported as likelihood ratios and if pre-test probabilitiesre available for the clinical manifestations defined for
utoantibody testing, the post-test probabilities can be
alculated based on Bayes’ theorem. 
Altogether, it should be anticipated that standardization of
utoantibody testing is not a realistic goal for the very near
uture. Harmonization, on the other hand, can be achieved
y implementing recommendations/guidelines at several 
evels. Considering that DM is a relatively rare disease,
uch harmonization requires a collaborative effort to define
 gating strategy and to obtain the relevant data, like reliable
est-characteristics and pre-test probabilities. 
. DM, rashes, and the antisynthetase syndrome 
Dr. Victoria Werth opened this session by discussing
he features that define a DM rash. She noted that the
ohan and Peter criteria defined DM for many years
165 , 166] . These criteria did not allow recognition of
myopathic DM patients, since patients had to have some
uscle abnormalities to be recognized as even possible DM.
ontheimer’s criteria for the skin findings of DM include
athognomonic findings of Gottron’s papules and Gottron’s
ign. Characteristic findings include heliotrope, periungual 
elangiectasias, dystrophic cuticles, and photodistributed 
iolaceous erythema. Secondary skin features of DM include
ubepidermal vesicle and/or blisters which could evolve
nto superficial erosion/ulcerations. Other secondary features
nclude vasculopathy, poikiloderma (hyperpigmentation 
nd hypopigmentation, telangiectasias, and superficial 
trophy), as well as cutaneous calcinosis. The International
yositis Classification Criteria Project (IMCCP) utilized 
 collaborative and scientific approach to develop criteria
hat would allow recognition of amyopathic DM, with
hree skin criteria determined as important to include
s criteria: heliotrope, Gottron’s papules, and Gottron’s
ign. The presence of two of the three skin variables allowed
ecognition of patients as having DM [2 , 3 , 167] . A skin biopsy
howing typical changes of interface dermatitis was included
s part of the selection criteria for subjects used in the criteria
tudy, and it was recommended to utilize skin biopsies in
ddition to the clinical criteria to avoid inclusion of mimickers
f DM. These new EULAR/ACR criteria allow classifying
myopathic DM in approximately 75% of patients [168] . 
There is now an ongoing collaborative effort to further
efine the skin variables, so that more CADM patients can
e correctly classified as DM. A pre-delphi, followed by
wo rounds of Delphi have narrowed potential classification
riteria from 54 to 22 items that are now being tested
rospectively in an international collaboration including 
ermatologists and rheumatologists. The variables to be
ested include morphology, distribution, symptoms, presence 
f myositis antibodies, and contextual factors such as
nterstitial lung disease (ILD) and muscle weakness. The
oal is to develop and validate skin criteria for DM so as
o correctly classify as many patients as possible, with the
arget group being patients with amyopathic DM. 













































































































a  Features of DM can be helpful in terms of determining risk
of ILD, with mechanics hands seen somewhat more often in
patients with ILD, although prevalent in those without ILD or
antisynthetase antibodies [169] . It is clear that antisynthetase
antibodies can be seen in patients with skin features of
DM, and thus defining DM with or without antisynthetase
antibodies may help define distinct subsets. Many patients
with DM or CADM and ILD do not have antisynthetase
antibodies, so there is a lot of overlap of systemic features.
MDA-5 antibodies define a subset of patients who may
have rapidly progressive ILD. MDA-5 patients have more
lung disease, skin ulcers, palmar papules, mechanics hands,
oral lesions, and alopecia [44] . Skin ulcers in DM can be
due to vasculopathy, vasculitis, excessive inflammation at
the interface between the dermis and epidermis, or due to
excoriations in response to pruritus. Antibodies are beginning
to help define phenotypes of disease. There is however,
a need for better standardization of measurement of DM
autoantibodies. A recent study showed just 14% of patients
with DM had MSAs and 21% had MSAs when testing was
done in commercial labs [170] . Hopefully the detection rate
of autoantibodies will improve with time and allow better
correlation with disease phenotype. 
To summarize, Dr. Werth noted that clinical findings in the
skin include both primary and secondary changes. The new
EULAR/ACR criteria allow identifying 75% of patients with
amyopathic DM. An ongoing prospective study will further
refine criteria for the patients with skin predominant disease.
Histology in about 80% of cases of DM show interface
dermatitis. There are some cases that don’t show that pattern
and that can make the diagnosis more difficult. The key is
clinical and pathological correlation. 
Next, Dr. Marianne de Visser discussed the significance
of DM-like features in antisynthetase syndrome, and whether
patients with aminoacyl transfer RNA synthetase (ARS)
autoantibodies and a rash should be considered to have DM.
The typical clinical findings of antisynthetase syndrome
(arthritis, myositis, and interstitial lung disease [defined
as classic triad manifestations]) are found in only 20% of
patients at the onset of the disease, reaching more than 50%
throughout follow-up [171] . Noguchi et al. [172] described
the dermatological findings in 51 patients with antisynthetase
syndrome. Mechanics hands were seen in 16 patients (31%),
although Gottron’s sign/papules and heliotrope rash which are
considered characteristic of DM were also reported (Gottron,
14 [27%]; heliotrope, 7 [14%]; both, 3 [6%]) in patients with
different ARS antibodies. Conversely, mechanic hands can
also be observed in DM. Ang et al. [169] reported that 3 out
of 3 DM patients with anti-MDA5 antibodies and 12 out of
17 DM subjects with anti-TIF1- γ had mechanic’s hands. 
As regards the histology, muscle biopsies taken from
antisynthetase syndrome patients show similarities with DM,
including necrotic and regenerating fibers scattered throughout
the muscle biopsy specimen, perimysial perivascular
mononuclear cell infiltrates and alkaline phosphatase
positivity of the perimysial connective tissue [172 , 173] ,
but there are also differences, i.e., necrotic muscle fibersocated in the perifascicular region are found in about half of
he antisynthetase syndrome muscle biopsies, whereas in DM
here is perifascicular atrophy and sarcoplasmic expression
f MxA in a fair proportion of the cases (55% and 77%,
espectively) [64] . 
Based on the above, one might argue that some
ntisynthetase syndrome patients have much in common
ith DM and could, in fact, be considered to have a form
f DM. However, Olivier Benveniste presented the counter
rgument, first recalling that the initial description of anti-Jo1
utoantibodies in 1980 was made in a series of 8 out of
6 PM patients (31%) and only 1 out of 22 DM patients
174] . The first series of antisynthetase syndrome cases in
990 described PM (not DM), ILD, and autoantibodies to
minoacyl-tRNA synthetase enzymes [175] . Furthermore, in
 recently published multiple correspondence analysis with
nsupervised hierarchical cluster analysis [176] , professor
enveniste and colleagues described 4 subgroups of patients:
BM, IMNM, DM and antisynthetase syndrome. Importantly,
M and antisynthetase syndrome were clearly separated in
his unsupervised analysis. By using the former Bohan and
eter classification criteria [177 , 178] , they observed that 95%
f antisynthetase patients are in the PM subgroup and only
% were classified DM. He also noted that although Gottron
ash/papules can sometimes be observed in patients with
SA, the skin biopsy from these patients do not stain positive
or MxA as they do in DM (as discussed by Dr. Fujimoto). 
Muscle pathology is also different between antisynthetase
yndrome and DM even if perifascicular atrophy can be
bserved in both conditions. In contrast to DM, antisynthetase
yndrome muscle biopsies are characterized by perifascicular
ecrosis, perimysial fragmentation [67] , HLA DR staining
f the perifasciculum [66] , absence of MxA upregulation
64] and nuclear abnormalities with actin inclusions [179] .
inally, the IFN signatures are also different between DM
nd antisynthetase syndrome, with type I being prominent in
M and type II predominant in antisynthetase syndrome. 
In summary, Professor Benveniste noted that differences
n each dimension (i.e., phenotype, MSA, skin pathology,
uscle pathology, and physiopathogenesis) strongly indicate
hat antisynthetase syndrome is a unique subgroup among
he different forms of myositis, including DM. 
0. Do DM-specific autoantibodies define distinct 
ubtypes of DM? 
Next, Professor Ingrid Lundberg summarized data
resented at the meeting bearing on the question of whether
he different DM-specific autoantibodies should be used
o define distinct DM subtypes. She reviewed the detailed
resentations given on clinical and histopathological features
f muscle and skin associated with the anti-TIF1- γ , anti-
XP2, anti-Mi2, anti-MDA5 and ant-SAE autoantibodies.
he group agreed that these data strongly suggest that
ifferent autoantibody specificities are associated with
ifferent clinical phenotypes. For example, anti-TIF1- γ and
nti-NXP2 autoantibodies are associated with malignancies
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Table 1 
ENMC 2018 dermatomyositis classification criteria. 
1. A DM classification can be made if the following clinical and skin biopsy features are present ∗: 
(a) Clinical exam findings (at least two of the following): Gottron’s sign, Gottron’s papules, and/or heliotrope rash. 
(b) Skin biopsy findings: interface dermatitis. 
2. A DM classification can be made if the following clinical features are present along with either DM muscle features ∗∗ or a DM-specific 
autoantibody ∗∗∗: 
(a) Clinical exam findings (at least one of the following): Gottron’s sign, Gottron’s papules, and/or heliotrope rash. 
∗Based on established skin criteria that allow classification of clinically amyopathic DM [2 , 3] . 
∗∗DM muscle features 
1. Proximal muscle weakness. 
2. Elevated muscle enzymes. 
3. Suggestive DM muscle biopsy findings: lymphocytic infiltrates (often perivascular), evidence of perifascicular disease (perifascicular 
predominant fibers that are pale on COX staining and/or positive on NCAM staining). 
4. Definitive DM muscle biopsy findings: perifascicular atrophy and/or perifascicular MxA overexpression with rare or absent perifascicular 
necrosis. 








• A classification of DM cannot be made in the absence of cutaneous DM features. 
• Patients with an antisynthetase autoantibody will be classified as having the antisynthetase syndrome and not DM. Antisynthetase syndrome 
patients with a DM-like rash will be classified as having “the antisynthetase syndrome with a DM-like rash”. 
• Patients with anti-HMGCR or anti-SRP autoantibodies will be classified as having IMNM and not DM. Anti-HMGCR + patients with a 
DM-like rash will be classified as having “anti-HMGCR myopathy with a DM-like rash”. Anti-SRP + patients with a DM-like rash will be 
classified as having “anti-SRP myopathy with a DM-like rash”. 
• Patients with a DM-specific autoantibody will be subclassified according to that autoantibody (e.g., anti-TIF1 γ DM, anti-NXP2 DM, etc.…) 
• Patients who have DM without a DM-specific autoantibody will be subclassified as having “autoantibody negative DM”. 
• Ulcerating lesions on the extensor surfaces of the metacarpophalangeal, proximal interphalangeal, and/or distal interphalangeal joints (as may be 
















































a  hereas anti-MDA5 autoantibodies are associated with RP-
LD, which is rarely found in anti-TIF1- γ - or anti-NXP2-
ositive patients [180] . Different skin features, distributions
nd severity of skin rash vary between these five MSA
ubgroups. Likewise, data show that anti-MDA5 and anti-
AE autoantibodies are often associated with mild muscle
eakness or amyopathic DM whereas patients with anti-Mi2
ntibodies often have severe muscle weakness. 
In addition, histopathological features in skin and muscle
re different between patients with different MSAs. For
xample, as presented by Professor Stenzel, muscle biopsies
rom patients with anti-Mi2 antibodies typically display
erimysial connective tissue changes with fragmentation 
nd alkaline phosphatase activity and biopsies from patients
ith anti-TIF1- γ autoantibodies often display perifascicular
hanges and MAC depositions on capillaries [68] . Of note,
xA staining was also different among subsets of DM
atients defined by different autoantibodies [64] . 
In summary, accumulating clinical and histopathological 
ata suggest that different pathophysiological mechanisms 
ay be involved in patients with different DM autoantibodies
eading to different types of skin rash and muscle pathology.
ifferences in immune mechanisms are further supported by
ssociations of different MSAs with different HLA types [91] .
Importantly, in most laboratories, about 25% of patients
ith DM test negative for currently identified autoantibodies;he clinical and histopathological features of these patients
equire further study. Moreover, whether these patients might
ave novel autoantibodies still needs to be addressed. 
1. Reaching consensus 
The group reached consensus about how to classify
atients with DM ( Table 1 ). The proposed new classification
ystem recognizes that DM autoantibodies are specific for
M and they now have an important role in the classification
cheme. Furthermore, the group reached consensus that DM
s not a homogeneous entity. Rather, each DM autoantibody
s associated with a distinctive clinical phenotype ( Table 2 )
nd DM autoantibodies can be used to define 6 different
ubtypes of DM: (1) anti-TIF1- γ DM, (2) anti-NXP2 DM,
3) anti-Mi2 DM, (4) anti-MDA5 DM, (5) anti-SAE DM,
nd (6) autoantibody negative DM. 
There was some lively discussion about whether the rare
atient with a DM autoantibody, muscle weakness, and a
uscle biopsy showing perifascicular atrophy, but who does
ot have a rash, should be diagnosed with DM. Ultimately,
n our newly proposed classification scheme, cutaneous DM
eatures, but not muscle involvement, is required for a patient
o be classified as DM. 
Importantly, patients with antisynthetase autoantibodies 
re considered to have a separate disease, the antisynthetase
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Table 2 
Clinical features associated with each dermatomyositis autoantibody in adults. 
Anti-Mi2 Anti-TIF1 γ Anti-NXP2 Anti-MDA5 Anti-SAE 
Prevalence among DM 5–20% 15–25% 15–25% 5–20% ∼5% 
Muscle 
Severity of weakness +++ + ++ + + 
Pattern of weakness Proximal Proximal Proximal/distal Proximal Proximal 
CK levels (mean peak) +++ ++ +++ + + 
Biopsy features 
Perifascicular atrophy ++ ++ ++ + ? 
Skin 
Gottron’s/heliotrope ++ +++ ++ ++ ? 
Ulcerations –/ + –/ + + +++ ? 
Calcinosis –/ + –/ + ++ –/ + ? 
Interstitial lung disease –/ + –/ + –/ + +++ + 


































Asyndrome, and are not considered to be within the
DM myositis type even if they have typical DM-skin
involvement. Similarly, patients with anti-HMGCR or anti-
SRP autoantibodies, even if they have rashes, are considered
to have IMNM and should not be classified as having DM. 
The group agreed that each DM subtype has different
clinical features and that each is likely to have different
underlying disease mechanisms. Therefore, future DM clinical
trials should give consideration to either (a) only including
DM patients with a particular defined autoantibody or (b)
stratifying patients by autoantibody status. As antisynthetase
patients have a distinct type of disease, even antisynthetase
patients with a rash should not be included in DM clinical
trials. 
Finally, and importantly, the proposed classification
criteria for DM and its autoantibody-associated subgroups
from this ENMC workshop need to be validated in clinical
cohorts. Ideally, this validation effort would occur as part
of a multicenter collaboration including a large number of
patients with different clinical profiles to allow comparisons
between different subgroups. Eventually, with longitudinal
follow up, time will tell if these subgroups vary in treatment
response and prognosis. 
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